UK markets closed
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • FTSE 250

    20,338.96
    +93.53 (+0.46%)
     
  • AIM

    933.20
    +4.84 (+0.52%)
     
  • GBP/EUR

    1.1820
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • BTC-GBP

    20,319.80
    +506.83 (+2.56%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • DOW

    33,761.05
    +424.38 (+1.27%)
     
  • CRUDE OIL

    91.88
    -2.46 (-2.61%)
     
  • GOLD FUTURES

    1,818.90
    +11.70 (+0.65%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • HANG SENG

    20,175.62
    +93.19 (+0.46%)
     
  • DAX

    13,795.85
    +101.34 (+0.74%)
     
  • CAC 40

    6,553.86
    +9.19 (+0.14%)
     

Novartis CFO: improved outlook for Sandoz has no impact on strategic review

  • Oops!
    Something went wrong.
    Please try again later.
FILE PHOTO: The Novartis logo is seen on the Swiss drugmaker's factory in Stein
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FRANKFURT (Reuters) - An improved earnings outlook for Sandoz, the generic-drug unit of Swiss pharmaceuticals giant Novartis, has no impact on the ongoing strategic review of the business, Novartis' finance chief said on Tuesday.

"I strongly believe one needs to follow the best-owner principle," Chief Financial Officer Harry Kirsch told journalists in a call following the release of second-quarter results.

(Reporting by Ludwig Burger)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting